Seven drugs slated for approval in 2025 could revolutionize treatment for various rare diseases. These include diazoxide choline for Prader-Willi syndrome, fitusiran for hemophilia, elamipretide for Barth syndrome, nipocalimab for myasthenia gravis, plozasiran for familial chylomicronemia syndrome, sebetralstat for hereditary angioedema, and taletrectinib for ROS1-positive non-small cell lung cancer. These drugs aim to improve the lives of those with rare conditions, demonstrating recent advancements in research, diagnosis, and treatment.
Governor’s office says cyber incident over as Cleveland Muni Court still closed – Cleveland 19 News
The Governor’s office has confirmed that the cyber incident affecting Cleveland Municipal Court has been resolved. However, the court remains closed as a precaution. The
